IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients
Abstract Background The ability of generating effective humoral immune responses to SARS-CoV-2 infection has not been clarified in lymphoma patients. The study aimed to investigate the antibody (Ab) production after SARS-Cov-2 infection and clarify the factors affecting the Ab generation in these pa...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | BMC Immunology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12865-024-00596-1 |
| _version_ | 1797355841308852224 |
|---|---|
| author | Huan Xie Jing Zhang Ran Luo Yan Qi Yizhang Lin Changhao Han Xi Li Dongfeng Zeng |
| author_facet | Huan Xie Jing Zhang Ran Luo Yan Qi Yizhang Lin Changhao Han Xi Li Dongfeng Zeng |
| author_sort | Huan Xie |
| collection | DOAJ |
| description | Abstract Background The ability of generating effective humoral immune responses to SARS-CoV-2 infection has not been clarified in lymphoma patients. The study aimed to investigate the antibody (Ab) production after SARS-Cov-2 infection and clarify the factors affecting the Ab generation in these patients. Patients & methods 80 lymphoma patients and 51 healthy controls were included in this prospective observational study. Clinical factors and treatment regimens affecting Ab positive rate (APR) and Ab levels were analyzed by univariate and multivariate methods. Results The anti-SARS-CoV-2 IgG APR and Ab levels in lymphoma patients were significantly lower than those in healthy controls. Lymphoma patients with COVID-19 vaccination had significantly higher APR and Ab levels compared with those without vaccination. Additionally, the use of dexamethasone for COVID-19 treatment had a negative impact on Ab levels. For the impact of treatment regimens on the APR and Ab levels, the results showed that patients treated with ≥ 6 times CD20 monoclonal Ab (mAb) and patients treated with autologous hematopoietic stem cell transplantation (ASCT) prior to infection produced a statistically lower APR and Ab levels compared with those treated with 1–5 times CD20 mAb and those treated without ASCT, respectively. Furthermore, multiple regression analysis indicated that the number of anti-CD20 treatment was an independent predictor for both APR and Ab levels. Conclusions Humoral immune response to SARS-CoV-2 infection was impaired in lymphoma patients partly due to anti-CD20 and ASCT treatment. COVID-19 vaccination may be more needed for these patients. |
| first_indexed | 2024-03-08T14:17:58Z |
| format | Article |
| id | doaj.art-35b9b110fe554845bfb4c935a16c67ab |
| institution | Directory Open Access Journal |
| issn | 1471-2172 |
| language | English |
| last_indexed | 2024-03-08T14:17:58Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Immunology |
| spelling | doaj.art-35b9b110fe554845bfb4c935a16c67ab2024-01-14T12:17:52ZengBMCBMC Immunology1471-21722024-01-0125111110.1186/s12865-024-00596-1IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patientsHuan Xie0Jing Zhang1Ran Luo2Yan Qi3Yizhang Lin4Changhao Han5Xi Li6Dongfeng Zeng7Department of Hematology, Daping Hospital, Army Medical UniversityDepartment of Hematology, Daping Hospital, Army Medical UniversityDepartment of Hematology, Daping Hospital, Army Medical UniversityDepartment of Hematology, Daping Hospital, Army Medical UniversityDepartment of Hematology, Daping Hospital, Army Medical UniversityDepartment of Hematology, Daping Hospital, Army Medical UniversityDepartment of Hematology, Daping Hospital, Army Medical UniversityDepartment of Hematology, Daping Hospital, Army Medical UniversityAbstract Background The ability of generating effective humoral immune responses to SARS-CoV-2 infection has not been clarified in lymphoma patients. The study aimed to investigate the antibody (Ab) production after SARS-Cov-2 infection and clarify the factors affecting the Ab generation in these patients. Patients & methods 80 lymphoma patients and 51 healthy controls were included in this prospective observational study. Clinical factors and treatment regimens affecting Ab positive rate (APR) and Ab levels were analyzed by univariate and multivariate methods. Results The anti-SARS-CoV-2 IgG APR and Ab levels in lymphoma patients were significantly lower than those in healthy controls. Lymphoma patients with COVID-19 vaccination had significantly higher APR and Ab levels compared with those without vaccination. Additionally, the use of dexamethasone for COVID-19 treatment had a negative impact on Ab levels. For the impact of treatment regimens on the APR and Ab levels, the results showed that patients treated with ≥ 6 times CD20 monoclonal Ab (mAb) and patients treated with autologous hematopoietic stem cell transplantation (ASCT) prior to infection produced a statistically lower APR and Ab levels compared with those treated with 1–5 times CD20 mAb and those treated without ASCT, respectively. Furthermore, multiple regression analysis indicated that the number of anti-CD20 treatment was an independent predictor for both APR and Ab levels. Conclusions Humoral immune response to SARS-CoV-2 infection was impaired in lymphoma patients partly due to anti-CD20 and ASCT treatment. COVID-19 vaccination may be more needed for these patients.https://doi.org/10.1186/s12865-024-00596-1LymphomaCOVID-19SARS-CoV-2AntibodyCD20 |
| spellingShingle | Huan Xie Jing Zhang Ran Luo Yan Qi Yizhang Lin Changhao Han Xi Li Dongfeng Zeng IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients BMC Immunology Lymphoma COVID-19 SARS-CoV-2 Antibody CD20 |
| title | IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients |
| title_full | IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients |
| title_fullStr | IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients |
| title_full_unstemmed | IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients |
| title_short | IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients |
| title_sort | igg antibody response to sars cov 2 infection and its influencing factors in lymphoma patients |
| topic | Lymphoma COVID-19 SARS-CoV-2 Antibody CD20 |
| url | https://doi.org/10.1186/s12865-024-00596-1 |
| work_keys_str_mv | AT huanxie iggantibodyresponsetosarscov2infectionanditsinfluencingfactorsinlymphomapatients AT jingzhang iggantibodyresponsetosarscov2infectionanditsinfluencingfactorsinlymphomapatients AT ranluo iggantibodyresponsetosarscov2infectionanditsinfluencingfactorsinlymphomapatients AT yanqi iggantibodyresponsetosarscov2infectionanditsinfluencingfactorsinlymphomapatients AT yizhanglin iggantibodyresponsetosarscov2infectionanditsinfluencingfactorsinlymphomapatients AT changhaohan iggantibodyresponsetosarscov2infectionanditsinfluencingfactorsinlymphomapatients AT xili iggantibodyresponsetosarscov2infectionanditsinfluencingfactorsinlymphomapatients AT dongfengzeng iggantibodyresponsetosarscov2infectionanditsinfluencingfactorsinlymphomapatients |